FYB2 Is a Potential Prognostic Biomarker for Hepatocellular Carcinoma
FYB2 (also known as C1orf168 or ARAP) is an adaptor protein involved in T-cell receptor (TCR)-mediated T-cell activation and adhesion. However, the correlation of FYB2 with prognosis and cancer needs further investigation. In this study, we analyzed the expression levels of FYB2 in hepatocellular ca...
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2022-11-01
|
| Series: | Livers |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2673-4389/2/4/27 |
| _version_ | 1797456668266594304 |
|---|---|
| author | Yifan Qu Xiaozhong Shen Xinpei Yuan Bing Lu |
| author_facet | Yifan Qu Xiaozhong Shen Xinpei Yuan Bing Lu |
| author_sort | Yifan Qu |
| collection | DOAJ |
| description | FYB2 (also known as C1orf168 or ARAP) is an adaptor protein involved in T-cell receptor (TCR)-mediated T-cell activation and adhesion. However, the correlation of FYB2 with prognosis and cancer needs further investigation. In this study, we analyzed the expression levels of FYB2 in hepatocellular carcinoma (LIHC) tumor tissues and correlated it with the pathological stages, survival outcomes, and tumor grades. We found that the expression of FYB2 was significantly downregulated in LIHC. Low FYB2 level leading to weak survival outcomes is linked with advanced tumor grades and elevated pathological stages. Cox regression analysis showed that FYB2 and AJCC-M stages can be used as independent prognostic factors for LIHC. GSEA analysis revealed that FYB2 would be notably correlated with the cellular metabolism-related pathways and particularly involved in the regulation of cancer-related pathways. Single-cell transcriptome analysis revealed that FYB2-positive cells were mainly distributed in hepatocytes, and compared with other cells, the upregulated genes of these cells were mainly enriched in metabolism-related functions. The results of the spatial transcriptome revealed that the expression of FYB2 in the adjacent area was higher than in the tumor area. These results showed that FYB2 is likely to be a new prognostic biomarker in LIHC and would help provide individual treatment decisions for LIHC patients. |
| first_indexed | 2024-03-09T16:11:07Z |
| format | Article |
| id | doaj.art-8f9a1c7407fb4af2b66303ae8f0f78bf |
| institution | Directory Open Access Journal |
| issn | 2673-4389 |
| language | English |
| last_indexed | 2024-03-09T16:11:07Z |
| publishDate | 2022-11-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Livers |
| spelling | doaj.art-8f9a1c7407fb4af2b66303ae8f0f78bf2023-11-24T16:14:30ZengMDPI AGLivers2673-43892022-11-012436137110.3390/livers2040027FYB2 Is a Potential Prognostic Biomarker for Hepatocellular CarcinomaYifan Qu0Xiaozhong Shen1Xinpei Yuan2Bing Lu3Medical College, Nantong University, Nantong 226000, ChinaMedical College, Nantong University, Nantong 226000, ChinaMedical College, Nantong University, Nantong 226000, ChinaBiological Sample Bank, Affiliated Hospital of Nantong University, Nantong 226001, ChinaFYB2 (also known as C1orf168 or ARAP) is an adaptor protein involved in T-cell receptor (TCR)-mediated T-cell activation and adhesion. However, the correlation of FYB2 with prognosis and cancer needs further investigation. In this study, we analyzed the expression levels of FYB2 in hepatocellular carcinoma (LIHC) tumor tissues and correlated it with the pathological stages, survival outcomes, and tumor grades. We found that the expression of FYB2 was significantly downregulated in LIHC. Low FYB2 level leading to weak survival outcomes is linked with advanced tumor grades and elevated pathological stages. Cox regression analysis showed that FYB2 and AJCC-M stages can be used as independent prognostic factors for LIHC. GSEA analysis revealed that FYB2 would be notably correlated with the cellular metabolism-related pathways and particularly involved in the regulation of cancer-related pathways. Single-cell transcriptome analysis revealed that FYB2-positive cells were mainly distributed in hepatocytes, and compared with other cells, the upregulated genes of these cells were mainly enriched in metabolism-related functions. The results of the spatial transcriptome revealed that the expression of FYB2 in the adjacent area was higher than in the tumor area. These results showed that FYB2 is likely to be a new prognostic biomarker in LIHC and would help provide individual treatment decisions for LIHC patients.https://www.mdpi.com/2673-4389/2/4/27FYB2prognostic biomarkerliver hepatocellular carcinoma |
| spellingShingle | Yifan Qu Xiaozhong Shen Xinpei Yuan Bing Lu FYB2 Is a Potential Prognostic Biomarker for Hepatocellular Carcinoma Livers FYB2 prognostic biomarker liver hepatocellular carcinoma |
| title | FYB2 Is a Potential Prognostic Biomarker for Hepatocellular Carcinoma |
| title_full | FYB2 Is a Potential Prognostic Biomarker for Hepatocellular Carcinoma |
| title_fullStr | FYB2 Is a Potential Prognostic Biomarker for Hepatocellular Carcinoma |
| title_full_unstemmed | FYB2 Is a Potential Prognostic Biomarker for Hepatocellular Carcinoma |
| title_short | FYB2 Is a Potential Prognostic Biomarker for Hepatocellular Carcinoma |
| title_sort | fyb2 is a potential prognostic biomarker for hepatocellular carcinoma |
| topic | FYB2 prognostic biomarker liver hepatocellular carcinoma |
| url | https://www.mdpi.com/2673-4389/2/4/27 |
| work_keys_str_mv | AT yifanqu fyb2isapotentialprognosticbiomarkerforhepatocellularcarcinoma AT xiaozhongshen fyb2isapotentialprognosticbiomarkerforhepatocellularcarcinoma AT xinpeiyuan fyb2isapotentialprognosticbiomarkerforhepatocellularcarcinoma AT binglu fyb2isapotentialprognosticbiomarkerforhepatocellularcarcinoma |